

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 February 2022 (03.02.2022)



(10) International Publication Number
WO 2022/026682 A1

(51) International Patent Classification:

A61N 1/18 (2006.01) A61P 35/00 (2006.01)
C12N 15/19 (2006.01) A61K 38/19 (2006.01)

(21) International Application Number:

PCT/US2021/043665

(22) International Filing Date:

29 July 2021 (29.07.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/058,026 29 July 2020 (29.07.2020) US

(71) Applicant: **ONCOSEC MEDICAL INCORPORATED**
[US/US]; 24 North Main Street, Pennington, New Jersey
08534 (US).

(72) Inventor: **TWITTY, Christopher G.**; 3565 General
Atomic Court, Suite 100, San Diego, California 92121 (US).

(74) Agent: **EKENA, Kirk et al.**; Alston & Bird LLP, 101 South
Tryon Street, One South at The Plaza, Suite 4000, Charlotte,
North Carolina 28280-4000 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: COMBINATION THERAPY FOR TREATMENT OF CANCER

week	Administration day(s)												
	1	2	3	4	5	6	7	8	9	10	11	12	13+
immunostimulatory cytokine 6 week cycle	1, 5	1					1, 5	1					...
immune checkpoint inhibitor 3 week cycle	1			1			1			1			...
chemotherapeutic 4 week cycle	1	1	1		1	1	1		1	1	1		...

each indicated treatment day is ± 2 days

FIG. 1

(57) Abstract: Described are methods and treatment schedules for treating cancer with intratumoral electroporation of an immunostimulatory cytokine combined with administration of an immune checkpoint inhibitor and a chemotherapeutic agent.

WO 2022/026682 A1